PTGX
Protagonist Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -6.7% ·
share flow +2.2% ·
net new positions -7.1%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 4.85K | $678,004 | n/a | −1 |
| Q2 2026 | 104 | +1 | 45.40M | $5.56B | +7 | −8 |
| Q1 2026 | 108 | -1 | 49.99M | $5.27B | +9 | −10 |
| Q4 2025 | 107 | +4 | 45.87M | $4.01B | +4 | n/a |
| Q3 2025 | 17 | 0 | 26.31M | $1.75B | +2 | −2 |
| Q2 2025 | 14 | -1 | 22.53M | $1.25B | +1 | −2 |
| Q1 2025 | 12 | +1 | 7.51M | $363.26M | +3 | −2 |
| Q4 2024 | 11 | -2 | 7.82M | $302.00M | n/a | −2 |
| Q3 2024 | 12 | +2 | 4.92M | $221.52M | +3 | −1 |
| Q2 2024 | 10 | n/a | 7.44M | $257.83M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 9.63M | n/a | $532.27M | 0.0% | n/c | 1 | SEC ↗ ×16 |
| 2 | The Vanguard Group ✦ (passive) | 4.36M | n/a | $240.90M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (passive) | 3.21M | +18.5% | $177.28M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 1.44M | +1.4% | $79.83M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 5 | Adage Capital Partners ✦ | 1.09M | +218.0% | $60.37M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 6 | Wellington Management ✦ | 1.04M | +5.1% | $57.36M | 0.0% | ▲ Add | 4 | SEC ↗ ×7 |
| 7 | T. Rowe Price ✦ | 936.70K | -29.1% | $51.77M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 8 | Fidelity (FMR) ✦ | 538.43K | n/a | $29.76M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 9 | Renaissance Technologies ✦ | 173.13K | -46.5% | $9.57M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 10 | Gotham Asset Management ✦ | 37.29K | +61.6% | $2.06M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 27.20K | -82.3% | $1.50M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 12 | Arrowstreet Capital ✦ | 17.86K | New | $986,901 | 0.0% | New | 1 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 17.41K | -56.6% | $962,195 | 0.0% | ▼ Trim | 5 | SEC ↗ ×4 |
| 14 | Millennium Management ✦ | 15.19K | -88.7% | $839,607 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Arrowstreet Capital | $986,901 | 0.0% |
Exited
| D. E. Shaw & Co. | $2.29M | was 0.0% |
| Two Sigma Investments | $277,635 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 310 holders, 71.79M shares, $7.31B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 46.03K sh · $6.53M
Officer · 12.60K sh · $1.79M
Officer, Director · 7.28K sh · $1.05M
Officer, Director · 63.55K sh · $9.29M
Officer, Director · 54.17K sh · $7.90M
Officer, Director · 34.24K sh · $5.09M
Officer, Director · 65.76K sh · $9.81M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology